The Office of Generic Drugs. U.S. Food and Drug Administration. What are generic drugs? http://www.fda.gov/cder/ogd/#Introduction (15.09.2010).
Ustawa z dnia 27 sierpnia 2004 r. o świadczeniach opieki zdrowotnej finansowanych ze środków publicznych (Dz.U.z 27 września 2004 r. Nr 210, poz. 2135, art. 38 i 62).
Prawo farmaceutyczne (Dz.U. z 6 września 2001 r. Nr 126, poz. 1381
Guideline on the investigation of bioequivalence. European Medicines Agency. CPMP/EWP/QWP/1401/98 Rev. 1/Corr.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (15.09.2010).
Kesselheim AS, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008; 300(21): 2514–2526.
Zarowitz BJ. The generic imperative. Geriatric Nursing 2008; 29: 4.
Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther 2003; 25(6): 1578–1592.
Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behavior 2004; 5:995–998.
Henderson JD, Esham RH. Generic substitution: issues for problematic drugs. South Med J 2001; 94(1): 16–21.
Pereira JA, Holbrook AM, Dolovich L, et al. Are brand-name and generic warfarin interchangeable? A survey of Ontario patients and physicians. Can J Clin Pharmacol 2005; 12(3): e229–e239.
Swenson CN, Fundak G. Observational cohort study of switching warfarin sodium products in a managed care organization.Am J Health Syst Pharm 2000; 57(5): 452–455.
Raport „Generic and innovative drug market In Central and Eastern Europe 2009. Comparative analysis, reimbursement Policie and development forecasts for 2009–2011”. PMR Publications, dział PMR, 2009.
Federman AD, Halm EA, Siu AL. Use of generic cardiovascular medications by elderly medicare beneficiaries receiving generalisk or cardiologist care. Med Care 2007; 45: 109–115.